Verastem Oncology cuts 30% staff, saves $8M annually. CEO says company will focus on early-stage RAS-targeting pipeline after Copiktra sales drop 18%. Cash runway into 2029.
Alpha Score of 40 reflects weak overall profile with moderate momentum, poor value, moderate quality, moderate sentiment.
Verastem Oncology will cut 30% of its workforce and restructure around its earlier-stage pipeline, the company said Thursday, as it winds down commercial efforts for its ovarian cancer drug Copiktra.
The layoffs are expected to save about $8 million in annual operating costs, net of severance and one-time charges of roughly $1 million. Verastem ended Q2 with $159 million in cash and investments. The restructuring will extend that runway into 2029, the company said in its earnings release.
The move effectively ends Verastem's bet on Copiktra as a commercial product. The PI3K inhibitor generated $2.7 million in net product revenue in Q2, down 18% from Q1 and about flat year-over-year. The drug has been under review from European regulators, who requested additional data on its benefit-risk profile – catalysts that triggered the broader strategic shift, CEO Dan Paterson said on a call with analysts. Verastem no longer plans to pursue a European approval.
“We're leaning into our early-stage pipeline,” Paterson said, citing the company's RAS-targeting programs and a planned Phase 2 trial in pancreatic cancer for its RAF/MEK inhibitor VS-6766 as priorities. VS-6766, in combination with defactinib, has drawn interest from researchers studying the RAS pathway, though it remains years from any regulatory decision.
Verastem's Alpha Score is 43 out of 100, a Mixed rating in the Industrials sector. The stock page shows more detail on the company's valuation and momentum profile. The restructuring does not change Verastem's U.S. commercial team for Copiktra, which will continue to support current patients, Paterson said.
For broader stock market analysis context, the biotech sector has been under pressure as investors rotate toward larger, cash-flow-positive names. Verastem's cost cuts and pipeline pivot fit a pattern seen across small-cap drug developers that launched products during the pandemic-era capital glut and now face a tighter funding environment.
What to track next: Enrollment data from the planned Phase 2 VS-6766 pancreatic trial, which Verastem expects to start by mid-2027. The RAS-targeting programs are earlier stage but represent the company's best chance at a meaningful pivot. Verastem's cash runway into 2029 gives it time – provided no new data or regulatory surprises emerge in the meantime.
Julissa Viana said the company will file its 10-Q with the SEC next week.
Reporting by AlphaScala.
Prepared with AlphaScala editorial tooling from the source reporting linked above. Indexable analysis may include a cited Alpha Score value. Publishing checks screen each story before release. Educational coverage, not personalized advice.